SC83288 is a clinical development candidate for the treatment of severe malaria
Severe malaria is a life-threatening infection with limited treatment options. Here, using a medicinal chemistry approach starting from amicarbalide, Pegoraroet al. identify a compound that, when delivered intravenously, can cure Plasmodium falciparuminfection in a humanized mouse model.
Main Authors: | , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2017-01-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/ncomms14193 |
id |
doaj-31209cc459aa4f289ae53a99dad149ad |
---|---|
record_format |
Article |
spelling |
doaj-31209cc459aa4f289ae53a99dad149ad2021-05-11T07:29:09ZengNature Publishing GroupNature Communications2041-17232017-01-018111710.1038/ncomms14193SC83288 is a clinical development candidate for the treatment of severe malariaStefano Pegoraro0Maëlle Duffey1Thomas D Otto2Yulin Wang3Roman Rösemann4Roland Baumgartner5Stefanie K Fehler6Leonardo Lucantoni7Vicky M Avery8Alicia Moreno-Sabater9Dominique Mazier10Henri J Vial11Stefan Strobl12Cecilia P Sanchez13Michael Lanzer144SC AG, Am Klopferspitz 19aDepartment of Infectious Diseases, Parasitology, Universitätsklinikum HeidelbergParasite Genomics, Wellcome Trust Sanger Institute, Wellcome Genome CampusDepartment of Infectious Diseases, Parasitology, Universitätsklinikum Heidelberg4SC Discovery GmbH, Am Klopferspitz 19a4SC AG, Am Klopferspitz 19a4SC AG, Am Klopferspitz 19aEskitis Institute for Drug Discovery, Griffith University, Don YoungEskitis Institute for Drug Discovery, Griffith University, Don YoungSorbonne Universités, UPMC Univ Paris 06, INSERM U1135, CNRS ERL 8255, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), 91 Bd de l’hôpitalSorbonne Universités, UPMC Univ Paris 06, INSERM U1135, CNRS ERL 8255, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), 91 Bd de l’hôpitalDynamique des Interactions Membranaires Normales et Pathologiques, CNRS UMR 5235, Université Montpellier II4SC Discovery GmbH, Am Klopferspitz 19aDepartment of Infectious Diseases, Parasitology, Universitätsklinikum HeidelbergDepartment of Infectious Diseases, Parasitology, Universitätsklinikum HeidelbergSevere malaria is a life-threatening infection with limited treatment options. Here, using a medicinal chemistry approach starting from amicarbalide, Pegoraroet al. identify a compound that, when delivered intravenously, can cure Plasmodium falciparuminfection in a humanized mouse model.https://doi.org/10.1038/ncomms14193 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Stefano Pegoraro Maëlle Duffey Thomas D Otto Yulin Wang Roman Rösemann Roland Baumgartner Stefanie K Fehler Leonardo Lucantoni Vicky M Avery Alicia Moreno-Sabater Dominique Mazier Henri J Vial Stefan Strobl Cecilia P Sanchez Michael Lanzer |
spellingShingle |
Stefano Pegoraro Maëlle Duffey Thomas D Otto Yulin Wang Roman Rösemann Roland Baumgartner Stefanie K Fehler Leonardo Lucantoni Vicky M Avery Alicia Moreno-Sabater Dominique Mazier Henri J Vial Stefan Strobl Cecilia P Sanchez Michael Lanzer SC83288 is a clinical development candidate for the treatment of severe malaria Nature Communications |
author_facet |
Stefano Pegoraro Maëlle Duffey Thomas D Otto Yulin Wang Roman Rösemann Roland Baumgartner Stefanie K Fehler Leonardo Lucantoni Vicky M Avery Alicia Moreno-Sabater Dominique Mazier Henri J Vial Stefan Strobl Cecilia P Sanchez Michael Lanzer |
author_sort |
Stefano Pegoraro |
title |
SC83288 is a clinical development candidate for the treatment of severe malaria |
title_short |
SC83288 is a clinical development candidate for the treatment of severe malaria |
title_full |
SC83288 is a clinical development candidate for the treatment of severe malaria |
title_fullStr |
SC83288 is a clinical development candidate for the treatment of severe malaria |
title_full_unstemmed |
SC83288 is a clinical development candidate for the treatment of severe malaria |
title_sort |
sc83288 is a clinical development candidate for the treatment of severe malaria |
publisher |
Nature Publishing Group |
series |
Nature Communications |
issn |
2041-1723 |
publishDate |
2017-01-01 |
description |
Severe malaria is a life-threatening infection with limited treatment options. Here, using a medicinal chemistry approach starting from amicarbalide, Pegoraroet al. identify a compound that, when delivered intravenously, can cure Plasmodium falciparuminfection in a humanized mouse model. |
url |
https://doi.org/10.1038/ncomms14193 |
work_keys_str_mv |
AT stefanopegoraro sc83288isaclinicaldevelopmentcandidateforthetreatmentofseveremalaria AT maelleduffey sc83288isaclinicaldevelopmentcandidateforthetreatmentofseveremalaria AT thomasdotto sc83288isaclinicaldevelopmentcandidateforthetreatmentofseveremalaria AT yulinwang sc83288isaclinicaldevelopmentcandidateforthetreatmentofseveremalaria AT romanrosemann sc83288isaclinicaldevelopmentcandidateforthetreatmentofseveremalaria AT rolandbaumgartner sc83288isaclinicaldevelopmentcandidateforthetreatmentofseveremalaria AT stefaniekfehler sc83288isaclinicaldevelopmentcandidateforthetreatmentofseveremalaria AT leonardolucantoni sc83288isaclinicaldevelopmentcandidateforthetreatmentofseveremalaria AT vickymavery sc83288isaclinicaldevelopmentcandidateforthetreatmentofseveremalaria AT aliciamorenosabater sc83288isaclinicaldevelopmentcandidateforthetreatmentofseveremalaria AT dominiquemazier sc83288isaclinicaldevelopmentcandidateforthetreatmentofseveremalaria AT henrijvial sc83288isaclinicaldevelopmentcandidateforthetreatmentofseveremalaria AT stefanstrobl sc83288isaclinicaldevelopmentcandidateforthetreatmentofseveremalaria AT ceciliapsanchez sc83288isaclinicaldevelopmentcandidateforthetreatmentofseveremalaria AT michaellanzer sc83288isaclinicaldevelopmentcandidateforthetreatmentofseveremalaria |
_version_ |
1721452106827694080 |